• Suite 42 Hollywood Specialist Centre 95 Monash Avenue Nedlands 6009 WA
  • 08 6424 8225
  • admin@nextgenoncology.com.au
img
  • Home
  • Team
  • Patient information
    • Understanding Anti-cancer therapies
    • Clinical Trials
    • After-Hours Clinical Support
    • Treatment Locations
    • Nutrition & cancer
    • Exercise & cancer
    • Patient Resources
    • Supportive & Palliative Care
    • Consultations
    • Appointment
  • Acute Oncology Service
  • Gallery
  • Referrals
  • Contact Us
img
img
×
  • Home
  • Team
  • Patient information
    • Understanding Anti-cancer therapies
    • Clinical Trials
    • After-Hours Clinical Support
    • Treatment Locations
    • Nutrition & cancer
    • Exercise & cancer
    • Patient Resources
    • Supportive & Palliative Care
    • Consultations
    • Appointment
  • Acute Oncology Service
  • Gallery
  • Referrals
  • Contact Us

Gallery

  1. Home
  2. Gallery

Interview VJ Oncology - Chicago ASCO 2023

TAS AGTA Edith Cowan University 2020

Your browser does not support the video tag.

Channel 9 news Interview

Channel News Interview

Society of Immunotherapy of Cancer (SITC) Washington 2018

eCancer Interview Chicago ASCO 2023

Your browser does not support the video tag.

Melanoma Late Breaking Abstract Chicago ASCO 2023

Your browser does not support the video tag.

Canadian Melanoma Conference Vancouver 2025

Your browser does not support the video tag.

Channel 7 Interview

Your browser does not support the video tag.

ABC News Interview

Your browser does not support the video tag.

ASCO Anual Meeting 2023

Prague 2015

Your browser does not support the video tag.

ESMO Berlin 2025

Trial of personalised immunotherapy cancer treatment shows promise on melanoma

Visit website →

Skin cancer breakthrough: WA researchers lead trials on personalised vaccines for cancer treatment

Visit website →

Ground-breaking WA research to match patients with immunotherapy treatment

Visit website →

Immunotherapy advances mean patients are living longer

Visit website →

Advanced melanoma patients first in Australia to receive tailor made cell therapy

Visit website →

ASCO 2023: Personalised vaccines may revolutionise cancer treatment

Visit website →

Finding a cure for melanoma

Visit website →

Australian oncologists shine at ESMO 2025

Visit website →

WA researchers to match patients with immunotherapy treatment

Visit website →

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

2024
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV
N Engl J Med 391(18) 1696-1708
Clinical Trial DOI: 10.1056/NEJMoa2402604

Top advances of the year: Melanoma

2024
Khattak MA, Luke JJ
Cancer 130(16) 2733-2738
Review DOI: 10.1002/cncr.35354

Melanoma update: is a cure now in sight?

2025
Liaqat S, Khattak MA
Intern Med J 55(8) 1242-1250
Review DOI: 10.1111/imj.70085

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial

2025
Dummer R, Robert C, Scolyer RA, Taube JM, Tetzlaff MT, Menzies AM, Hill A, Grob JJ, Portnoy DC, Lebbe C, Khattak MA, Cohen J, Bar-Sela G, Mehmi I, Shapira-Frommer R, Meyer N, Webber AL, Ren Y, Fukunaga-Kalabis M, Krepler C, Long GV
Nat Med 31(1) 144-151
Clinical Trial DOI: 10.1038/s41591-024-03411-x

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

2024
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T
Lancet 403(10427) 632-644
Clinical Trial DOI: 10.1016/S0140-6736(23)02268-7

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study

2024
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV
J Clin Oncol 42(14) 1619-1624
Clinical Trial DOI: 10.1200/JCO.23.02355

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

2022
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM
Lancet 399(10336) 1718-1729
Clinical Trial DOI: 10.1016/S0140-6736(22)00562-1

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

2023
Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Khattak MA, Mihalcioiu C, Jang S, Cowey CL, Smith AD, Hawk N, Chen K, Diede SJ, Krepler C, Long GV
J Clin Oncol 41(1) 75-85
Clinical Trial DOI: 10.1200/JCO.22.00221

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial

2025
Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Gershenwald JE, Sondak VK
Ann Surg Oncol 32(4) 2756-2764
Clinical Trial DOI: 10.1245/s10434-024-16642-6

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

2022
Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, Khattak A, Burge M, Harris M, Lynam J, Nott L, Day F, Hayes T, McLachlan SA, Lee B, Ptak J, Silliman N, Dobbyn L, Popoli M, Hruban R, Lennon AM, Papadopoulos N, Kinzler KW, Vogelstein B, Tomasetti C, Gibbs P
N Engl J Med 386(24) 2261-2272
Clinical Trial DOI: 10.1056/NEJMoa2200075

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

2024
Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C
Eur J Cancer 211 114327
Clinical Trial DOI: 10.1016/j.ejca.2024.114327

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy

2020
Abed A, Calapre L, Lo J, Correia S, Bowyer S, Chopra A, Watson M, Khattak MA, Millward M, Gray ES
J Immunother Cancer 8(2) e001620
Research Article DOI: 10.1136/jitc-2020-001620

PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

2020
Khattak MA, Reid A, Freeman J, Pereira M, McEvoy A, Lo J, Frank MH, Meniawy T, Didan A, Spencer I, Amanuel B, Millward M, Ziman M, Gray E
Oncologist 25(3) e520-e527
Research Article DOI: 10.1634/theoncologist.2019-0557

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced Melanoma

2020
Khattak A, Oey O, Gandhi A, Reid AL, Abed A, Calapre L, Morici M, Chopra A, Meniawy T, Millward M, Ziman M, Gray ES
Research Article
Research Article

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

2020
Khattak MA, Abed A, Reid AL, McEvoy AC, Millward M, Ziman M, Gray ES
Front Oncol 10 1041
Research Article DOI: 10.3389/fonc.2020.01041

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

2018
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C
N Engl J Med 378(19) 1789-1801
Clinical Trial DOI: 10.1056/NEJMoa1802357

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial

2025
Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan SA, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P
Nat Med 31(5) 1509-1518
Clinical Trial DOI: 10.1038/s41591-025-03579-w

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

2022
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C
NEJM Evid 1(11) EVIDoa2200214
Clinical Trial DOI: 10.1056/EVIDoa2200214

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

2024
Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM
Lancet Oncol 25(9) 1202-1212
Clinical Trial DOI: 10.1016/S1470-2045(24)00338-3

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

2024
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA
J Immunother Cancer 12(3) e007501
Clinical Trial DOI: 10.1136/jitc-2023-007501

Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC

2025
Gibbs P, Abubaker K, Wang D, Feng Z, Hamad J, Liao J, Stroh C, Vlassak S, Heinrich K, Khattak A, Scheuenpflug J
Clin Colorectal Cancer 24(3) 352-361.e14
Research Article DOI: 10.1016/j.clcc.2025.03.004

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

2022
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM
Eur J Cancer 176 207-217
Clinical Trial DOI: 10.1016/j.ejca.2022.08.004

Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer

2025
McKenzie J, Wong V, Mendis S, Wong R, Kosmider S, To YH, Nott L, Shapiro J, Torres J, Lee B, Jalali A, Lim SH, Caird S, Khattak A, Gibbs P
Clin Colorectal Cancer 24(3) 362-368
Research Article DOI: 10.1016/j.clcc.2025.04.001

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

2022
Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanello C, Wicky A, Heywood R, Tran L, Batty K, Dimitriou F, Stansfeld A, Allayous C, Schwarze JK, Mooradian MJ, Klein O, Mehmi I, Roberts-Thomson R, Maurichi A, Yeoh HL, Khattak A, Zimmer L, Blank CU, Ramelyte E, Kähler KC, Roy S, Ascierto PA, Michielin O, Lorigan PC, Johnson DB, Plummer R, Lebbe C, Neyns B, Sullivan R, Hamid O, Santinami M, McArthur GA, Haydon AM, Long GV, Menzies AM, Carlino MS
J Immunother Cancer 10(7) e004668
Research Article DOI: 10.1136/jitc-2022-004668

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma

2023
Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB
Eur J Cancer 194 113354
Research Article DOI: 10.1016/j.ejca.2023.113354

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

2021
Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A
Br J Cancer 124(3) 574-580
Research Article DOI: 10.1038/s41416-020-01121-y

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

2023
Lee J, Ahmed T, Maurichi A, Di Guardo L, Stagno AM, Warburton L, Taylor AM, Livingstone E, Rehman S, Khattak A, Kahler KC, Vanella V, Atkinson V, Millward M, Schadendorf D, Johnson DB, Ascierto PA, Hauschild A, Lo SN, Long GV, Menzies AM, Carlino MS
Eur J Cancer 179 87-97
Research Article DOI: 10.1016/j.ejca.2022.11.009

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

2023
Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, Dulgar O, Eroglu Z, Yeoh HL, Haydon A, Lodde GC, Livingstone E, Khattak A, Kähler K, Hausschild A, McArthur GA, Menzies AM, Long G, Wang W, Carlino MS
J Immunother Cancer 11(3) e006629
Research Article DOI: 10.1136/jitc-2022-006629

KEYNOTE-D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma

2022
Long GV, Ferrucci PF, Khattak A, Meniawy TM, Ott PA, Chisamore M, Trolle T, Hyseni A, Heegaard E
Future Oncol 18(31) 3473-3480
Clinical Trial DOI: 10.2217/fon-2022-0694

Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors

2023
Khan A, Welman CJ, Abed A, O'Hanlon S, Redfern A, Azim S, Lopez P, Singh F, Khattak A
Cancers (Basel) 15(5) 1382
Research Article DOI: 10.3390/cancers15051382

Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study

2020
Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, Mula-Hussain L, Errihani H, Khattak A, De Guzman RB, Mathias C, Alkaiyat MOF, Jradi H, Rolfo C
JCO Glob Oncol 6 1428-1438
Research Article DOI: 10.1200/GO.20.00351

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

2020
Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F
J Immunother Cancer 8(2) e001681
Clinical Trial DOI: 10.1136/jitc-2020-001681

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

2021
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM
Lancet Oncol 22(5) 655-664
Clinical Trial DOI: 10.1016/S1470-2045(21)00081-4

PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

2022
Eggermont AM, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A
Future Oncol
Clinical Trial

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

2018
Lee DH, Tsao MS, Kambartel KO, Isobe H, Huang MS, Barrios CH, Khattak A, de Marinis F, Kothari S, Arunachalam A, Cao X, Burke T, Valladares A, de Castro J
PLoS One 13(8) e0202865
Research Article DOI: 10.1371/journal.pone.0202865

Utilisation of geriatric assessment in oncology - a survey of Australian medical oncologists

2019
To THM, Soo WK, Lane H, Khattak A, Steer C, Devitt B, Dhillon HM, Booms A, Phillips J
J Geriatr Oncol 10(2) 216-221
Research Article DOI: 10.1016/j.jgo.2018.07.004

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

2021
Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, Helwig C, Dussault I, Ojalvo LS, Isambert N
Target Oncol 16(4) 435-446
Clinical Trial DOI: 10.1007/s11523-021-00809-2

Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status

2021
Travers A, Jalali A, Begbie S, Semira C, Kosmider S, Ananda S, Wong R, Lee M, Shapiro J, Burge M, Yip D, Torres J, Ma B, Nott L, Dean A, Tie J, Khattak A, Lim S, Wong HL, Gibbs P
Clin Colorectal Cancer 20(1) e21-e34
Research Article DOI: 10.1016/j.clcc.2020.08.002

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

2020
Degeling K, Wong HL, Koffijberg H, Jalali A, Shapiro J, Kosmider S, Wong R, Lee B, Burge M, Tie J, Yip D, Nott L, Khattak A, Lim S, Caird S, Gibbs P, IJzerman M
Pharmacoeconomics 38(11) 1263-1275
Research Article DOI: 10.1007/s40273-020-00951-1

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

2020
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S
JAMA Oncol 6(4) 519-527
Research Article DOI: 10.1001/jamaoncol.2019.5570
img

At our oncology practice, we are driven by a single unifying mission: to deliver exceptional, evidence-based cancer care with compassion, precision, and unwavering dedication.

Useful Links

  • Home
  • About Us
  • Gallery
  • Appointments
  • Contact Us

Our Services

  • Anti-Cancer Therapies
  • Clinical Trials
  • Treatment Locations
  • Supportive & Palliative Care
  • Consultations
  • Nutrition & cancer
  • Acute Oncology

Contact Us

  • ADDRESS
    Suite 42 Hollywood Specialist Centre 95 Monash Avenue Nedlands 6009 WA
  • PHONE
    08 6424 8225
  • Fax
    08 9200 5050
  • EMAIL
    admin@nextgenoncology.com.au

© Copyright 2025 Design by Futuresol | All Rights Reserved.